Keyphrases
Hepatocellular Carcinoma
100%
Liver Transplantation
60%
Hepatitis C Virus
53%
Liver
40%
Cirrhosis
35%
Hepatitis C
34%
Fibrosis
32%
Hepatic Stellate Cells
29%
Liver Disease
25%
Liver Fibrosis
23%
Chronic Hepatitis C
22%
Ribavirin
21%
Nonalcoholic Steatohepatitis
20%
Hepatic Fibrosis
20%
Hepatic Stellate Cell Activation
18%
Tumor
18%
United States
16%
Liver Transplant Recipients
16%
Sustained Virological Response
15%
Chronic Liver Disease
15%
Hepatitis C Virus Infection
14%
Liver Biopsy
14%
Non-alcoholic Fatty Liver Disease (NAFLD)
14%
Liver Injury
14%
Antifibrotic
13%
Liver Cancer
13%
AIDS/HIV
13%
Sorafenib
12%
Co-infected Patients
12%
Advanced Hepatocellular Carcinoma
12%
Hepatocytes
11%
Stellate Cells
11%
Hepatitis B Virus
11%
Primary Biliary Cirrhosis
11%
Fibrogenic
10%
Drug-induced Liver Injury
10%
Transplantation
10%
Kruppel-like Factor 6 (KLF6)
10%
Confidence Interval
10%
Hepatitis C Treatment
10%
Direct-acting Antivirals
10%
Hepatitis B
9%
Pegylated Interferon
9%
Risk Factors
9%
Sofosbuvir
9%
Clinical Trials
9%
Interferon-α (IFN-α)
9%
Fibrogenesis
9%
Alcoholic Hepatitis
9%
Antiretroviral Therapy
8%
Chronic Hepatitis B
8%
Placebo
8%
Transforming Growth Factor-β
8%
Autoimmune Hepatitis
8%
Post-liver Transplantation
8%
Infected Patients
7%
HIV Patients
7%
Response Rate
7%
Hepatitis C Virus Genotypes
7%
Hepatitis C Virus RNA
6%
Portal Hypertension
6%
Extracellular Matrix
6%
Hazard Ratio
6%
Overall Survival
6%
Inflammation
6%
Patient Survival
6%
Advanced Fibrosis
6%
Alpha-fetoprotein
6%
Alcoholic Liver Disease
6%
Gene Signature
6%
Primary Sclerosing Cholangitis
6%
MELD Score
6%
Cirrhotic Patients
6%
Steatosis
6%
Apoptosis
5%
Clinical Outcomes
5%
Combination Therapy
5%
High Risk
5%
Allograft
5%
Acute Liver Failure
5%
Gene Expression
5%
Hepatic Fibrogenesis
5%
Stellate Cell Activation
5%
Metabolic-associated Fatty Liver Disease (MAFLD)
5%
Intestinal Transplantation
5%
Chronic Hepatitis C Virus Infection
5%
Adverse Events
5%
Etiology
5%
Genotype 1
5%
Living Donor Liver Transplantation
5%
Ascites
5%
Phase II Trial
5%
Immune Response
5%
Hepatology
5%
Liver Function
5%
New York City
5%
Intrahepatic Cholangiocarcinoma (iCCA)
5%
Liver Cirrhosis
5%
Hepatotoxicity
5%
Medicine and Dentistry
Hepatocellular Carcinoma
86%
Liver Transplantation
56%
Fibrosis
39%
Hepatitis C Virus
36%
Hepatitis C
35%
Liver Cirrhosis
33%
Liver Fibrosis
31%
Liver Disease
30%
Liver Graft
25%
Hepatic Stellate Cell
25%
Neoplasm
23%
Nonalcoholic Fatty Liver
23%
Human Immunodeficiency Virus
22%
Disease
20%
Liver Injury
17%
Transplantation
17%
Infection
16%
Fibrogenesis
15%
Hepatitis B Virus
15%
Malignant Neoplasm
13%
Hepatitis B
13%
Liver Cancer
12%
Liver Biopsy
12%
Chronic Hepatitis C
12%
Stellate Cell
11%
Recurrent Disease
11%
Allograft
11%
Chronic Liver Disease
11%
Hepatocyte
11%
Portal Hypertension
10%
Prevalence
9%
Primary Biliary Cirrhosis
9%
Biological Marker
9%
Cell Activation
9%
Alcohol Liver Disease
8%
Antiviral Therapy
8%
Ribavirin
8%
Toxic Hepatitis
8%
Immunity
8%
Steatohepatitis
7%
Fatty Liver
7%
Diseases
7%
Hepatitis Virus
7%
Antivirus Agent
7%
Biopsy Technique
7%
Clinical Trial
6%
Sorafenib
6%
Chronic Hepatitis B
6%
Autoimmune Hepatitis
6%
Cholangiocarcinoma
6%
Steatosis
6%
Living Donors
6%
Extracellular Matrix
6%
Ascites
6%
Diagnosis
5%
Mixed Infection
5%
Injury
5%
Programmed Cell Death
5%
Overall Survival
5%
COVID-19
5%
Magnetic Resonance Imaging
5%
Bilirubin
5%
Placebo
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
71%
Hepatitis C Virus
46%
Hepatitis C
35%
Fibrosis
33%
HIV
29%
Liver Fibrosis
28%
Liver Cirrhosis
24%
Liver Disease
22%
Ribavirin
20%
Nonalcoholic Fatty Liver
19%
Disease
19%
Chronic Hepatitis C
18%
Liver Injury
18%
Neoplasm
17%
Antivirus Agent
16%
Infection
15%
Hepatitis B Virus
15%
Malignant Neoplasm
13%
Sorafenib
12%
Liver Cancer
11%
Placebo
11%
Chronic Hepatitis B
11%
Clinical Trial
11%
Hepatitis B
10%
Chronic Liver Disease
9%
Biological Marker
9%
Peginterferon
9%
Adverse Event
9%
Recurrent Disease
8%
Toxic Hepatitis
8%
Interferon
8%
Mixed Infection
8%
Sofosbuvir
8%
Virus Hepatitis
7%
Prevalence
7%
Inflammation
7%
Hepatotoxicity
7%
Diseases
7%
Combination Therapy
6%
Fatty Liver
6%
Overall Survival
6%
Ethanol
6%
Alcohol Liver Disease
6%
Hepatitis C Virus Genotype 1
6%
Autoimmune Hepatitis
6%
Injury
5%
Antiviral Therapy
5%
Receptor
5%